Engineering Immunity | Optimizing Metabolism | Extending Life
info@neolaiabio.com
Conquer Inflammation:
Engineering Cellular Resilience
For Better Healthspan Through Precision Molecular Science
At Neolaia, we pioneer next-generation therapeutics that enhance cellular resilience, reduce inflammation, and extend healthspan.
Our breakthrough non-cell-depleting catalytic CD38 inhibitor disrupts inflammation-based cellular aging through NAD+ restoration, transforming treatment for:
- Advanced immunological disorders
- Metabolic optimization
- Precision weight management
- Enhanced muscle performance
- Sustained cellular energy
- And beyond
Our Frontier Matrix
Compelling Evidence
NAD+ plays critical role in mitochondrial + cellular health: our precise targeting of CD38-expressing cells enables the optimal therapeutic window
Patient Need
We're honing-in on the 2 highest-value indications with robust preclinical + clinical scientific validation: Obesity + Inflammatory Pulmonary Fibrosis
Market Scale
Our solution has the opportunity to touch 30M+ addressable patients with up to $30B global market opportunity
Lead Programs:
Validated Science + Clear Commercial Paths
Inflammation, fibrosis and accelerated aging are drivers of disease pathophysiology: CD38 plays a key role.
Idiopathic Pulmonary Fibrosis
Obesity /
GLP-1 Induced Myopenia
Expanded pipeline info coming soon.
Request a confidential investor briefing for advance insight.
Who We Are
Neolaia at a glance
- Pre-clinical biotech founded November 2023, focused on NAD+ regulation for age-related diseases
- Expert scientific leadership bringing unparalleled expertise in NAD+ biology and drug development
- $7M seed funding supporting our targeted research and development pipeline
- Efficient hybrid model combining virtual operations with CROs and NC Biolabs facilities
- AI-enhanced screening platform identifying promising drug candidates with precision
- Integrated research capabilities including biophysical assays, crystallography, and metabolomics
- Clear market focus on establishing leadership in the NAD+ therapeutic space
Get in Touch with Us
©Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.